The Relevance of New Drug Combinations for Modern Tuberculosis Treatment - A Patent Perspective

2013 ◽  
Vol 8 (2) ◽  
pp. 130-138
Author(s):  
Alessandra Pinheiro ◽  
Marcus Souza
Keyword(s):  
Drug Combinations ◽  
Tuberculosis Treatment ◽  
New Drug

Production of Orally Applicable New Drug or Drug Combinations from Natural Origin Capsaicinoids for Human Medical Therapy

2010 ◽  
Vol 16 (10) ◽  
pp. 1197-1208 ◽  
Author(s):  
Gyula Mozsik ◽  
Tibor Past ◽  
Andras Domotor ◽  
Monika Kuzma ◽  
Pal Perjesi
Keyword(s):  
Medical Therapy ◽  
Drug Combinations ◽  
Natural Origin ◽  
New Drug

scholarly journals Breaktrough drug combination for Congenital Junctional Ectopic Tachycardia: a pediatric case report.

2021 ◽  
Author(s):  
Giovanni Di Marco ◽  
Angelica De Nigris ◽  
Giangiacomo Di Nardo
Keyword(s):  
Case Report ◽  
Drug Combination ◽  
Therapeutic Strategy ◽  
Drug Combinations ◽  
Suboptimal Control ◽  
Antiarrhythmic Agents ◽  
Pediatric Case ◽  
Junctional Ectopic Tachycardia ◽  
New Drug ◽  
Conventional Drug

Introduction: Congenital Junctional Ectopic Tachycardia (JET) is a rare tachyarrhythmia that remains difficult to manage with suboptimal control in the majority of cases. Methods: Here, we report the successful use of Ivabradine in combination with Flecainide for the therapy of congenital JET resistant to multiple antiarrhythmic agents. Results: This new drug combination was effective in completely suppressing JET . Conclusion: Ivabradine in combination with Flecainide may be considered a new therapeutic strategy of congenital JET with satisfactory efficacy/tolerability ratio in patients resistant to conventional drug combinations.

scholarly journals Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment

2012 ◽  
Vol 16 (4) ◽  
pp. 480-485 ◽  
Author(s):  
D. Lamunu ◽  
K. N. Chapman ◽  
P. Nsubuga ◽  
G. Muzanyi ◽  
Y. Mulumba ◽  
...  
Keyword(s):  
Multicenter Trial ◽  
Tuberculosis Treatment ◽  
New Drug ◽  
International Multicenter

scholarly journals AIDS researchers emphasize new drug combinations

1997 ◽  
Vol 15 (3) ◽  
pp. 215-215
Author(s):  
Jeffrey L Fox
Keyword(s):  
Drug Combinations ◽  
New Drug

New drug combinations for the treatment of murine AIDS and macrophage protection

2001 ◽  
Vol 31 (3) ◽  
pp. 248-252 ◽  
Author(s):  
A. Fraternale ◽  
A. Casabianca ◽  
A. Tonelli ◽  
L. Chiarantini ◽  
G. Brandi ◽  
...  
Keyword(s):  
Drug Combinations ◽  
New Drug ◽  
Murine Aids

Update on New Drug Combinations for Melanoma

2002 ◽  
Vol 24 (2) ◽  
pp. 32-34
Author(s):  
David Gillis
Keyword(s):  
Drug Combinations ◽  
New Drug

scholarly journals Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against Mycobacterium abscessus

2020 ◽  
Vol 64 (5) ◽  
Author(s):  
Clément Raynaud ◽  
Wassim Daher ◽  
Françoise Roquet-Banères ◽  
Matt D. Johansen ◽  
Jozef Stec ◽  
...  
Keyword(s):  
Bactericidal Activity ◽  
Mycobacterium Abscessus ◽  
Drug Combinations ◽  
New Drugs ◽  
Addition Compound ◽  
Content Type ◽  
Synergistic Interactions ◽  
New Drug ◽  
Clinical Potential

ABSTRACT New drugs or therapeutic combinations are urgently needed against Mycobacterium abscessus. Previously, we demonstrated the potent activity of indole-2-carboxamides 6 and 12 against M. abscessus. We show here that these compounds act synergistically with imipenem and cefoxitin in vitro and increase the bactericidal activity of the β-lactams against M. abscessus. In addition, compound 12 also displays synergism with imipenem and cefoxitin within infected macrophages. The clinical potential of these new drug combinations requires further evaluation.

Sign in / Sign up

Export Citation Format

Share Document